TORNTPHARM: Revenue and EBITDA surged; integration synergies support a gradual recovery and margin gains
Czytanie zajmuje mniej niż 1 minutę
Q2 revenue rose 51% and operating EBITDA rose 54%, while integration temporarily affected JB’s international sales. Cost synergies are ahead of plan, and management expects improving H2 margins and a gradual recovery in JB growth.
Based on Torrent Pharmaceuticals Ltd [TORNTPHARM] Q2 26/27 Audio Transcript — Oct. 23 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr